Headlines about Edge Therapeutics (NASDAQ:EDGE) have trended positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edge Therapeutics earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 48.6285920367726 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s analysis:
- FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease (markets.businessinsider.com)
- Global Epilepsy Therapeutics Market Will Reach USD 5,900 Million by 2024: Zion Market Research (globenewswire.com)
- Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments (forextv.com)
- Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation (seekingalpha.com)
- Pain Therapeutics’ opioid drug fails to gain FDA approval (pharmaphorum.com)
Separately, ValuEngine upgraded Edge Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $14.50.
Shares of Edge Therapeutics traded down $0.02, reaching $0.91, on Friday, MarketBeat.com reports. 148,487 shares of the company’s stock traded hands, compared to its average volume of 181,691. Edge Therapeutics has a 12-month low of $0.84 and a 12-month high of $17.77.
Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.12.
About Edge Therapeutics
Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.
Featured Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.